Over 25 years pharmaceutical experience: portfolio management, evaluation and deployment of new technologies, and quantitative biology.  Research emphasized the use of complex, physiologically relevant cellular systems for target validation, lead generation, SAR support, and biomarker discovery. Early adopter of phenotypic drug discovery (PDD) strategies, scientific founder of Lilly’s Open Innovation drug discovery venture,  advocate for the international PDD community.  Consultation for AI-Biotech startups, academia, and instrument companies.